| Symbol | ACRS |
|---|---|
| Name | ACLARIS THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 701 LEE ROAD,SUITE 103, WAYNE, Pennsylvania, 19087, United States |
| Telephone | +1 484 - 324-7933 |
| Fax | — |
| — | |
| Website | https://www.aclaristx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001557746 |
| Description | Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777. Additional info from NASDAQ: |
2026-06-08 20:15
SCHIFF ANDREW N 🟡 adjusted position in 53.3K shares (3 derivative) of Aclaris Therapeutics, Inc. (ACRS) at $4.71 Transaction Date: Jun 04, 2026 | Filing ID: 000002
Read more
2026-06-08 20:15
Mehra Anand 🟡 adjusted position in 53.3K shares (3 derivative) of Aclaris Therapeutics, Inc. (ACRS) at $4.71 Transaction Date: Jun 04, 2026 | Filing ID: 000002
Read more
2026-06-08 20:15
Humphries William D. 🟡 adjusted position in 53.3K shares (3 derivative) of Aclaris Therapeutics, Inc. (ACRS) at $4.71 Transaction Date: Jun 04, 2026 | Filing ID: 000002
Read more
2026-06-08 20:15
Molineaux Christopher P. 🟡 adjusted position in 53.3K shares (3 derivative) of Aclaris Therapeutics, Inc. (ACRS) at $4.71 Transaction Date: Jun 04, 2026 | Filing ID: 000003
Read more
2026-06-08 20:15
MILANO VINCENT 🟡 adjusted position in 53.3K shares (3 derivative) of Aclaris Therapeutics, Inc. (ACRS) at $4.71 Transaction Date: Jun 04, 2026 | Filing ID: 000002
Read more
2026-06-08 20:15
GOWEN MAXINE 🟡 adjusted position in 53.3K shares (3 derivative) of Aclaris Therapeutics, Inc. (ACRS) at $4.71 Transaction Date: Jun 04, 2026 | Filing ID: 000004
Read more
2026-06-04 20:01
(99% Neutral) ACLARIS THERAPEUTICS, INC. (ACRS) Announces Regulatory Update
Read more
2026-05-28 12:30
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Read more
2026-05-12 22:49
New Form SCHEDULE 13G/A - Aclaris Therapeutics, Inc. <b>Filed:</b> 2026-05-12 <b>AccNo:</b> 0001213900-26-055376 <b>Size:</b> 13 KB
Read more
2026-05-08 12:30
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06648434 | MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreat… | Phase1 | Metastatic Pancreatic Ductal Adenocarcinoma | Recruiting | 2025-06-13 | 2030-05-31 | ClinicalTrials.gov |
| NCT07011706 | ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis | Phase2 | Atopic Dermatitis | Active_Not_Recruiting | 2025-05-30 | 2026-10-01 | ClinicalTrials.gov |
| NCT06374459 | Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor… | Phase1 | Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer | Recruiting | 2025-01-30 | 2032-05-31 | ClinicalTrials.gov |
| NCT06585202 | Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatit… | Phase2 | Atopic Dermatitis | Completed | 2024-08-19 | 2025-03-31 | ClinicalTrials.gov |
| NCT05791474 | ATI-2231 in Advanced Solid Tumor Malignancies | Phase1 | Advanced Solid Tumor | Withdrawn | 2023-11-15 | 2025-06-30 | ClinicalTrials.gov |
| NCT05511519 | Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthr… | Phase2 | Psoriatic Arthritis | Terminated | 2022-07-12 | 2024-01-03 | ClinicalTrials.gov |
| NCT05432596 | Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Der… | Phase2 | Atopic Dermatitis | Completed | 2022-05-11 | 2023-11-14 | ClinicalTrials.gov |
| NCT05279417 | ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Mo… | Phase2 | Rheumatoid Arthritis | Completed | 2022-02-01 | 2023-10-11 | ClinicalTrials.gov |
| NCT05216224 | ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppura… | Phase2 | Hidradenitis Suppurativa | Completed | 2021-12-29 | 2023-01-24 | ClinicalTrials.gov |
| NCT04524858 | Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS) | Phase2 | Cryopyrin-Associated Periodic Syndrome | Terminated | 2020-10-23 | 2021-02-25 | ClinicalTrials.gov |
| NCT04598269 | Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis | Phase2 | Atopic Dermatitis | Completed | 2020-09-30 | 2021-04-22 | ClinicalTrials.gov |
| NCT04247815 | Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate… | Phase2 | Rheumatoid Arthritis | Completed | 2020-03-16 | 2021-02-04 | ClinicalTrials.gov |
| NCT03812510 | Safety Study of A-101 Topical Solution for the Treatment of Common Warts | Phase3 | Common Wart | Completed | 2019-02-07 | 2019-12-20 | ClinicalTrials.gov |
| NCT03759340 | ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Un… | Phase2 | Alopecia Areata | Terminated | 2019-01-15 | 2019-09-11 | ClinicalTrials.gov |
| NCT03687372 | Study of A-101 Topical Solution for the Treatment of Common Warts | Phase3 | Common Wart | Completed | 2018-09-17 | 2019-09-06 | ClinicalTrials.gov |
| NCT03691831 | A Study of A-101 Topical Solution for the Treatment of Common Warts | Phase3 | Common Wart | Completed | 2018-09-13 | 2019-07-09 | ClinicalTrials.gov |
| NCT03585296 | A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis | Phase2 | Atopic Dermatitis | Completed | 2018-07-10 | 2019-04-25 | ClinicalTrials.gov |
| NCT03594227 | ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, A… | Phase2 | Alopecia | Completed | 2018-06-11 | 2019-06-18 | ClinicalTrials.gov |
| NCT03551821 | Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects W… | Phase2 | Alopecia Areata | Completed | 2018-04-11 | 2018-11-06 | ClinicalTrials.gov |
| NCT03495817 | A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI… | Phase2 | Androgenetic Alopecia | Completed | 2018-03-22 | 2019-10-30 | ClinicalTrials.gov |
| NCT03487588 | An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Sebor… | Phase4 | Seborrheic Keratosis | Completed | 2018-03-21 | 2018-11-14 | ClinicalTrials.gov |
| NCT03468855 | A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo | Phase2 | Vitiligo | Completed | 2018-03-19 | 2019-10-16 | ClinicalTrials.gov |
| NCT03315689 | Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Univers… | Phase2 | Alopecia Universalis (AU) | Completed | 2017-12-14 | 2019-06-20 | ClinicalTrials.gov |
| NCT03380390 | Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participan… | Phase4 | Rosacea | Completed | 2017-12-04 | 2018-06-15 | ClinicalTrials.gov |
| NCT03354637 | A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata | Phase2 | Alopecia Areata | Terminated | 2017-11-29 | 2019-09-10 | ClinicalTrials.gov |
| NCT03210337 | A Phase2 of A-101 Topical Solution in Subjects With Common Warts | Phase2 | Common Wart | Completed | 2017-08-01 | 2018-03-16 | ClinicalTrials.gov |
| NCT03278028 | A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Co… | Phase2 | Common Wart | Completed | 2017-07-13 | 2018-03-01 | ClinicalTrials.gov |
| NCT03224598 | A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra | Phase2 | Dermatosis Papulosa Nigra | Completed | 2017-06-26 | 2019-01-08 | ClinicalTrials.gov |
| NCT03148691 | A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Tre… | Phase2 | Seborrheic Keratosis | Completed | 2017-05-17 | 2018-04-03 | ClinicalTrials.gov |
| NCT02667275 | A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrhei… | Phase3 | Seborrheic Keratosis | Completed | 2016-01-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02667288 | An Open-Label Safety Study of A-101 Solution | Phase3 | Seborrheic Keratosis | Completed | 2016-01-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02667236 | A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis. | Phase3 | Seborrheic Keratosis | Completed | 2016-01-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02669862 | A Study of A-101 Solution in Subjects With Common Warts. | Phase2 | Common Warts | Completed | 2015-12-21 | 2016-09-16 | ClinicalTrials.gov |
| NCT02260180 | Study of A-101 for the Treatment of Seborrheic Keratosis | Phase2 | Seborrheic Keratosis | Completed | 2014-10-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT02160626 | Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis | Phase2 | Seborrheic Keratosis | Completed | 2014-06-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01986920 | Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Sebor… | Phase1 | Seborrheic Keratosis (SK) | Completed | 2013-10-22 | 2014-02-25 | ClinicalTrials.gov |
Total clinical trials: 36
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Vehicle Solution | Other | Phase PHASE3 | Seborrheic Keratosis | COMPLETED | NCT02667275 |
| A-101 Solution | Other | Phase PHASE3 | Seborrheic Keratosis | COMPLETED | NCT02667275 |
| Vehicle Solution | Other | Phase PHASE3 | Seborrheic Keratosis | COMPLETED | NCT02667236 |
| A-101 Solution | Other | Phase PHASE3 | Seborrheic Keratosis | COMPLETED | NCT02667236 |
| A-101 Solution | Other | Phase PHASE3 | Seborrheic Keratosis | COMPLETED | NCT02667288 |
| Vehicle Solution | Other | Phase PHASE2 | Common Warts | COMPLETED | NCT02669862 |
| A-101 Solution 45 | Other | Phase PHASE2 | Common Warts | COMPLETED | NCT02669862 |
| A-101 Solution 40 | Other | Phase PHASE2 | Common Warts | COMPLETED | NCT02669862 |
| A-101 Vehicle | Other | Phase PHASE1 | Seborrheic Keratosis (SK) | COMPLETED | NCT01986920 |
| A-101 40% | Other | Phase PHASE1 | Seborrheic Keratosis (SK) | COMPLETED | NCT01986920 |
| A-101 32.5% | Other | Phase PHASE1 | Seborrheic Keratosis (SK) | COMPLETED | NCT01986920 |
| A-101 25% | Other | Phase PHASE1 | Seborrheic Keratosis (SK) | COMPLETED | NCT01986920 |
| A-101 (32.5) Topical Solution | Other | Phase PHASE2 | Seborrheic Keratosis | COMPLETED | NCT02160626 |
| A-101 (40) Topical Solution | Other | Phase PHASE2 | Seborrheic Keratosis | COMPLETED | NCT02160626 |
| A-101 Vehicle | Other | Phase PHASE2 | Seborrheic Keratosis | COMPLETED | NCT02160626 |
| A-101 Vehicle Solution | Other | Phase PHASE2 | Common Wart | COMPLETED | NCT03278028 |
| A-101 Topical Solution | Other | Phase PHASE2 | Common Wart | COMPLETED | NCT03278028 |
| A-101 Vehicle Solution | Other | Phase PHASE2 | Common Wart | COMPLETED | NCT03210337 |
| A-101 Topical Solution | Other | Phase PHASE2 | Common Wart | COMPLETED | NCT03210337 |
| A-101 | Other | Phase PHASE2 | Seborrheic Keratosis | COMPLETED | NCT03148691 |
| Energy-Based Therapy | Drug | Phase PHASE4 | Rosacea | COMPLETED | NCT03380390 |
| Oxymetazoline HCL 1.0% Cream | Other | Phase PHASE4 | Rosacea | COMPLETED | NCT03380390 |
| A-101 Topical Solution | Other | Phase PHASE4 | Seborrheic Keratosis | COMPLETED | NCT03487588 |
| ATI-50002 | Other | Phase PHASE2 | Alopecia Areata | COMPLETED | NCT03551821 |
| ATI-502 | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT03585296 |
| A-101 Topical Solution 40% | Other | Phase PHASE2 | Dermatosis Papulosa Nigra | COMPLETED | NCT03224598 |
| Placebo | Other | Phase PHASE2 | Alopecia Areata | TERMINATED | NCT03354637 |
| ATI-50002 low dose | Other | Phase PHASE2 | Alopecia Areata | TERMINATED | NCT03354637 |
| ATI-50002 high dose | Other | Phase PHASE2 | Alopecia Areata | TERMINATED | NCT03354637 |
| ATI-50002 | Other | Phase PHASE2 | Alopecia Universalis (AU) | COMPLETED | NCT03315689 |
| Vehicle | Other | Phase PHASE2 | Alopecia Universalis (AU) | COMPLETED | NCT03315689 |
| Placebo | Other | Phase PHASE2 | Alopecia | COMPLETED | NCT03594227 |
| ATI-501 800mg BID (High dose) | Other | Phase PHASE2 | Alopecia | COMPLETED | NCT03594227 |
| ATI-501 600mg BID (Mid dose) | Other | Phase PHASE2 | Alopecia | COMPLETED | NCT03594227 |
| ATI-501 400mg BID (Low dose) | Other | Phase PHASE2 | Alopecia | COMPLETED | NCT03594227 |
| vehicle | Other | Phase PHASE3 | Common Wart | COMPLETED | NCT03687372 |
| A-101 | Other | Phase PHASE3 | Common Wart | COMPLETED | NCT03687372 |
| ATI 502 0.46% Topical Solution | Other | Phase PHASE2 | Alopecia Areata | TERMINATED | NCT03759340 |
| Vehicle | Other | Phase PHASE3 | Common Wart | COMPLETED | NCT03691831 |
| Active | Other | Phase PHASE3 | Common Wart | COMPLETED | NCT03691831 |
| A-101 | Other | Phase PHASE3 | Common Wart | COMPLETED | NCT03812510 |
| ATI-50002 topical solution | Other | Phase PHASE2 | Vitiligo | COMPLETED | NCT03468855 |
| A-101 | Other | Phase PHASE2 | Seborrheic Keratosis | COMPLETED | NCT02260180 |
| ATI-50002 | Other | Phase PHASE2 | Androgenetic Alopecia | COMPLETED | NCT03495817 |
| Methotrexate | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT04247815 |
| Placebo oral tablet | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT04247815 |
| ATI-450 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT04247815 |
| ATI-450 | Other | Phase PHASE2 | Cryopyrin-Associated Periodic Syndrome | TERMINATED | NCT04524858 |
| Vehicle | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT04598269 |
| ATI-1777 | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT04598269 |
| ATI-2231 | Other | Phase PHASE1 | Advanced Solid Tumor | WITHDRAWN | NCT05791474 |
| ATI-450 20 mg oral tablet BID | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT05279417 |
| Methotrexate | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT05279417 |
| Placebo oral tablet | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT05279417 |
| ATI-450 50 mg oral tablet BID | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT05279417 |
| Vehicle | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT05432596 |
| ATI-1777 0.5% w/w | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT05432596 |
| ATI-1777 1.0% w/w | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT05432596 |
| ATI-1777 2.0% w/w | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT05432596 |
| Placebo Oral Tablet | Other | Phase PHASE2 | Psoriatic Arthritis | TERMINATED | NCT05511519 |
| ATI-450 | Other | Phase PHASE2 | Psoriatic Arthritis | TERMINATED | NCT05511519 |
| Placebo oral tablet | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT05216224 |
| ATI-450 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT05216224 |
| ATI-2138 | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT06585202 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT07011706 |
| ATI-045 | Other | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT07011706 |
| Denosumab | Other | Phase PHASE1 | Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer | RECRUITING | NCT06374459 |
| Zoledronic acid | Other | Phase PHASE1 | Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer | RECRUITING | NCT06374459 |
| Capecitabine | Other | Phase PHASE1 | Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer | RECRUITING | NCT06374459 |
| Zumsemetinib | Other | Phase PHASE1 | Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer | RECRUITING | NCT06374459 |
| mFOLFIRINOX | Other | Phase PHASE1 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06648434 |
| Zunsemetinib | Other | Phase PHASE1 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06648434 |
| mFOLFIRINOX | Other | Phase PHASE1 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06648434 |
| Zunsemetinib | Other | Phase PHASE1 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06648434 |
| mFOLFIRINOX | Other | Phase PHASE1 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06648434 |
| Zunsemetinib | Other | Phase PHASE1 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06648434 |
| mFOLFIRINOX | Other | Phase PHASE1 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06648434 |
| Zunsemetinib | Other | Phase PHASE1 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06648434 |
| mFOLFIRINOX | Other | Phase PHASE1 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06648434 |
| Zunsemetinib | Other | Phase PHASE1 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06648434 |
| mFOLFIRINOX | Other | Phase PHASE1 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06648434 |
| Zunsemetinib | Other | Phase PHASE1 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06648434 |
| ATI-045 | DRUG | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT07011706 |
| mFOLFIRINOX | DRUG | Phase PHASE1 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06648434 |
| Zunsemetinib | DRUG | Phase PHASE1 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT06648434 |
| ATI-2138 | DRUG | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT06585202 |
| Denosumab | DRUG | Phase PHASE1 | Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer | RECRUITING | NCT06374459 |
| Zoledronic acid | DRUG | Phase PHASE1 | Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer | RECRUITING | NCT06374459 |
| Capecitabine | DRUG | Phase PHASE1 | Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer | RECRUITING | NCT06374459 |
| Zumsemetinib | DRUG | Phase PHASE1 | Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer | RECRUITING | NCT06374459 |
| ATI-2231 | DRUG | Phase PHASE1 | Advanced Solid Tumor | WITHDRAWN | NCT05791474 |
| Placebo Oral Tablet | DRUG | Phase PHASE2 | Psoriatic Arthritis | TERMINATED | NCT05511519 |
| ATI-1777 0.5% w/w | DRUG | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT05432596 |
| ATI-1777 1.0% w/w | DRUG | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT05432596 |
| ATI-1777 2.0% w/w | DRUG | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT05432596 |
| ATI-450 20 mg oral tablet BID | DRUG | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT05279417 |
| ATI-450 50 mg oral tablet BID | DRUG | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT05279417 |
| BSI-045B | BIOLOGICAL | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT05114889 |
| ATI-1777 | DRUG | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT04598269 |
| Methotrexate | DRUG | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT05279417 |
| Placebo oral tablet | DRUG | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT05279417 |
| ATI-450 | DRUG | Phase PHASE2 | Psoriatic Arthritis | TERMINATED | NCT05511519 |
| ATI 502 0.46% Topical Solution | DRUG | Phase PHASE2 | Alopecia Areata | TERMINATED | NCT03759340 |
| Active | DRUG | Phase PHASE3 | Common Wart | COMPLETED | NCT03691831 |
| vehicle | OTHER | Phase PHASE3 | Common Wart | COMPLETED | NCT03687372 |
| ATI-501 800mg BID (High dose) | DRUG | Phase PHASE2 | Alopecia | COMPLETED | NCT03594227 |
| ATI-501 600mg BID (Mid dose) | DRUG | Phase PHASE2 | Alopecia | COMPLETED | NCT03594227 |
| ATI-501 400mg BID (Low dose) | DRUG | Phase PHASE2 | Alopecia | COMPLETED | NCT03594227 |
| ATI-502 | DRUG | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT03585296 |
| ATI-50002 topical solution | DRUG | Phase PHASE2 | Vitiligo | COMPLETED | NCT03468855 |
| Energy-Based Therapy | DEVICE | Phase PHASE4 | Rosacea | COMPLETED | NCT03380390 |
| Oxymetazoline HCL 1.0% Cream | DRUG | Phase PHASE4 | Rosacea | COMPLETED | NCT03380390 |
| Placebo | DRUG | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT07011706 |
| ATI-50002 low dose | DRUG | Phase PHASE2 | Alopecia Areata | TERMINATED | NCT03354637 |
| ATI-50002 high dose | DRUG | Phase PHASE2 | Alopecia Areata | TERMINATED | NCT03354637 |
| ATI-50002 | DRUG | Phase PHASE2 | Alopecia Areata | COMPLETED | NCT03551821 |
| Vehicle | DRUG | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT05432596 |
| A-101 Topical Solution 40% | DRUG | Phase PHASE2 | Dermatosis Papulosa Nigra | COMPLETED | NCT03224598 |
| A-101 Vehicle Solution | DRUG | Phase PHASE2 | Common Wart | COMPLETED | NCT03278028 |
| A-101 Topical Solution | DRUG | Phase PHASE4 | Seborrheic Keratosis | COMPLETED | NCT03487588 |
| A-101 Solution 45 | DRUG | Phase PHASE2 | Common Warts | COMPLETED | NCT02669862 |
| A-101 Solution 40 | DRUG | Phase PHASE2 | Common Warts | COMPLETED | NCT02669862 |
| Vehicle Solution | DRUG | Phase PHASE2 | Common Warts | COMPLETED | NCT02669862 |
| A-101 Solution | DRUG | Phase PHASE3 | Seborrheic Keratosis | COMPLETED | NCT02667288 |
| A-101 | DRUG | Phase PHASE3 | Common Wart | COMPLETED | NCT03812510 |
| A-101 (32.5) Topical Solution | DRUG | Phase PHASE2 | Seborrheic Keratosis | COMPLETED | NCT02160626 |
| A-101 (40) Topical Solution | DRUG | Phase PHASE2 | Seborrheic Keratosis | COMPLETED | NCT02160626 |
| A-101 Vehicle | DRUG | Phase PHASE2 | Seborrheic Keratosis | COMPLETED | NCT02160626 |
| A-101 40% | DRUG | Phase PHASE1 | Seborrheic Keratosis (SK) | COMPLETED | NCT01986920 |
| A-101 32.5% | DRUG | Phase PHASE1 | Seborrheic Keratosis (SK) | COMPLETED | NCT01986920 |
| A-101 25% | DRUG | Phase PHASE1 | Seborrheic Keratosis (SK) | COMPLETED | NCT01986920 |
Total products: 131